TORONTO, June 1, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (FSE: 8TV) (OTC: AINMF) announces its attendance at the American Society of Clinical Oncology (ASCO) Conference in Chicago, IL. This prestigious event brings together leading experts, researchers, and professionals from the oncology field to exchange knowledge, discuss advancements, and explore innovative solutions.
The conference presents an excellent opportunity for NetraMark to engage with industry leaders to demonstrate how its proprietary industry leading Artificial Intelligence (AI) based products, NetraAI and NetraGPT, can transform late stage oncology clinical trials by identifying the influential variables that drive response to candidate medicines.
"At NetraMark, we understand how to maximize the discovery of unique trial enrichment insights from small clinical study populations. This addresses a major challenge facing oncology sponsors developing novel therapeutics and new combination therapies," said Josh Spiegel, President of NetraMark. "We are excited to participate in the ASCO Conference and present our state-of-the-art solutions that can help sponsors enrich their clinical trials and drive better results."
"Oncology has been one of my primary areas of focus academically and I look forward to engaging with colleagues to discuss how our technology is primed to help pharmaceutical companies run trials with a higher rate of success. Understanding a patient population and the underlying mechanisms of response is particularly difficult in Oncology and I'm excited to discuss our unique and powerful approach," said Dr. Joseph Geraci, CTO / CSO NetraMark.
NetraMark will be participating in the event from June 2 to June 6, 2023.
About NetraMark
NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the opportunity the conference presents to the Company to engage with industry leaders to demonstrate how the Company's technology can transform late stage oncology clinical trials and identify influential variables that drive response to candidate medicines, the ability of NetraMark to maximize the discovery of unique trial enrichment insights from small clinical study populations to help sponsors enrich their clinical trials and drive better results and to help pharmaceutical companies run trials with a higher rate of success which are based on NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management's Discussion and Analysis for the quarter ended March 31, 2023. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE NetraMark Holdings Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2023/01/c0145.html